On August 20, 2024, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK), announces that its partner GSK has received US Food and Drug Administration (FDA) Breakthrough Therapy Designation for its B7-H3-targeted antibody-drug conjugate in relapsed or refractory extensive-stage small-cell lung cancer.
This FDA Breakthrough Therapy Designation is supported by data from the ongoing ARTEMIS-001 Phase 1 open-label, multi-center trial of over 200 patients evaluating the safety, tolerability, and preliminary anti-tumor activity in locally advanced or metastatic solid tumors, including relapsed or refractory ES-SCLC, conducted by Hansoh Pharma. Results from this trial will be presented at the 2024 World Conference on Lung Cancer (WCLC) taking place from September 7 to 10, 2024 in San Diego, California, USA.
On 20 December 2023, Hansoh Pharma entered into an exclusive license agreement with GSK to grant GSK a worldwide exclusive license (excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture and commercialize HS-20093.
As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma will continue to expand its innovation collaborations with global partners, efficiently promote the implementation of first-in-class (FIC) or best-in-class (BIC) products, and benefit more patients using its expanding range of breakthrough innovative therapies.
ABOUT HS-20093
HS-20093 is a novel investigational B7-H3-targeted ADC composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple phase I and II clinical trials in China.
About Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases, and is dedicated to improving human health through continuous innovation. Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years, and is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June, 2019 (stock code: 03692.HK). For more information, please visit www.hspharm.com.
Foresights Statement
This article aims to provide information about Hansoh Pharmaceutical Group Co., Ltd. or its affiliates, including their subsidiaries (collectively, the "Company") and does not constitute a disclosure of information about the Company or any investment recommendations.
The information released in this article may contain some foresights statements, such as those relating to business and product prospects, or the Company's plans, beliefs, expectations, or strategies. These statements constitute predictions based on data from speculative assumptions, which in no way is a guarantee of future developments, given its nature being subject to risks and uncertainties, some of which are beyond the Company's control and difficult to predict, and these statements should be used with caution by investors in making investment decisions. The use of the words "commit", "expect", "believe", "predict", "anticipate", or any other similar words used to describe information about the Company constitute foresights statements. The Company undertakes no obligation to update or revise these foresights statements, and neither the Company, nor any of its directors, employees, or agents bear any responsibility for any of these foresights statements being unachievable or becoming incorrect.
All information in this press release speaks only as of the date of release and the Company assumes no responsibility or obligation to update or revise this information in the event that new information emerges, future events occur, or other situations arise, unless required by the law. For obtaining information relating to the listed company only, investors are advised to refer to announcements and financial reports of Hansoh Pharma (03692.HK).
